세계의 면역 종양학 어세이 시장 규모 : 제품별, 기술별, 적응증별, 용도별, 지역별, 범위 및 예측

Immuno Oncology Assays Market Size And Forecast

Immuno Oncology Assays Market size was valued at USD 3.87 Billion in 2024 and is projected to reach USD 5.78 Billion by 2031 , growing at a CAGR of 5.70% from 2024 to 2031. Global immuno-oncology assays refer to a range of diagnostic tests designed to evaluate the immune response to cancer and assess the effectiveness of immunotherapy treatments. These assays are crucial for identifying specific biomarkers, such as immune checkpoint inhibitors and tumor-infiltrating lymphocytes, which help tailor personalized treatment plans for cancer patients. The applications of immuno-oncology assays extend across various cancer types, guiding clinical decision-making, monitoring treatment responses, and predicting patient outcomes.

The future of this field looks promising, driven by advancements in biomarker discovery, next-generation sequencing technologies, and increasing investments in immunotherapy research. As the demand for personalized cancer treatment grows, the global immuno-oncology assays market is expected to expand significantly, enhancing the precision of cancer therapies and improving patient survival rates.

Global Immuno Oncology Assays Market Dynamics

The key market dynamics that are shaping the global immuno-oncology assays market include:

Key Market Drivers:

Rising Incidence of Cancer:

The increasing prevalence of cancer worldwide is a significant driver for the immuno-oncology assays market. According to the World Health Organization (WHO), cancer cases are expected to rise to 29.5 million globally by 2040, up from 19.3 million in 2020. This surge in cancer incidence is driving the demand for effective diagnostic tools, including immuno-oncology assays.

Growing Adoption of Immunotherapy:

The rising acceptance and success of immunotherapy in cancer treatment are propelling the market. A report by the American Cancer Society states that approximately 50% of new cancer drugs approved in recent years are immunotherapies, highlighting the need for assays that can identify suitable candidates for these treatments.

Advancements in Biomarker Discovery:

Innovations in biomarker research and technology are enhancing the development of immuno-oncology assays. The National Institutes of Health (NIH) reported a 17% increase in research funding for cancer biomarkers between 2021 and 2022, driving advancements that improve assay accuracy and effectiveness in predicting treatment responses.

Increased Government Funding and Support:

Governments are increasingly investing in cancer research and immunotherapy development, which bolsters the immuno-oncology assays market. For instance, the National Cancer Institute (NCI) in the U.S. allocated approximately $6 billion for cancer research in 2023, with a significant portion dedicated to advancing immunotherapy and related diagnostic technologies.

Key Challenges:

High Cost of Assays:

The development and implementation of advanced immuno-oncology assays can be expensive, which may limit access for some healthcare facilities and patients. High costs can also hinder widespread adoption, especially in developing regions where budget constraints are a concern.

Regulatory Hurdles:

Navigating the regulatory landscape for immuno-oncology assays can be complex and time-consuming. Stringent regulatory requirements for clinical validation and approval may delay the introduction of new assays into the market, impacting timely patient access to innovative diagnostics.

Data Interpretation Complexity:

The interpretation of results from immuno-oncology assays can be challenging due to the complexity of immune responses and tumor biology. Clinicians may require specialized training to accurately interpret the results, which can complicate the integration of these assays into routine clinical practice.

Limited Standardization:

There is a lack of standardization across different immuno-oncology assays, which can lead to variability in results and outcomes. This inconsistency makes it difficult for clinicians to compare results and makes regulatory approval processes more complicated.

Key Trends:

Integration of Artificial Intelligence (AI) and Machine Learning:

The use of AI and machine learning in the analysis of immuno-oncology assay data is gaining traction. These technologies can enhance data interpretation, identify patterns, and improve the accuracy of predictions related to treatment responses, ultimately leading to better patient outcomes.

Personalized Medicine Focus:

There is a growing emphasis on personalized medicine, with immuno-oncology assays playing a crucial role in tailoring treatments to individual patients based on their specific tumor characteristics and immune profiles. This trend is expected to drive the demand for more sophisticated and precise assays.

Partnerships and Collaborations:

Increasing collaborations between biotechnology companies, research institutions, and healthcare providers are emerging to foster innovation in immuno-oncology assays. These partnerships aim to combine expertise and resources to develop and commercialize new diagnostic tools effectively.

Expansion into Emerging Markets:

The immuno-oncology assays market is witnessing expansion into emerging markets as healthcare infrastructure improves and awareness of cancer treatments increases. This trend presents significant growth opportunities for companies looking to tap into previously underserved regions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Immuno Oncology Assays Market Regional Analysis

Here is a more detailed regional analysis of the global immuno oncology assays market:

North America:

North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The region is home to leading pharmaceutical and biotechnology companies that are actively engaged in the development of innovative immuno-oncology therapies. According to the National Cancer Institute (NCI), an estimated 1.9 million new cancer cases will be diagnosed in the U.S. in 2024, which underscores the urgent need for effective diagnostic and treatment options.

Additionally, the regulatory environment in North America, particularly in the United States, is supportive of rapid innovations in cancer diagnostics and therapeutics. The U.S. Food and Drug Administration (FDA) has expedited the approval process for immuno-oncology assays, facilitating quicker access to market. This regulatory advantage, combined with high healthcare spending per capita, enhances the region's leadership in the immuno-oncology assays market.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure. The region is witnessing a surge in cancer cases due to factors such as an aging population and lifestyle changes, making the development and implementation of immuno-oncology therapies critical. According to the World Health Organization (WHO), cancer cases in Asia are projected to reach over 7.1 million by 2030, highlighting a significant demand for advanced diagnostic tools and treatments.

Governments in countries like China, Japan, and India are investing heavily in cancer research and healthcare infrastructure to combat the rising cancer burden. For instance, the Chinese government allocated approximately $2.5 billion for cancer research in its latest five-year plan, which aims to improve cancer detection and treatment. This commitment is expected to accelerate the adoption of immuno-oncology assays in the region.

Global Immuno Oncology Assays Market: Segmentation Analysis

The Global Immuno Oncology Assays Market is segmented on the basis of Product, Application, Indication, Technology, and Geography.

Immuno Oncology Assays Market, By Product

• Consumables
• Software and Services
• Instruments

Based on Product, the Global Immuno Oncology Assays Market is segmented into Consumables, Software and Services, and Instruments. The Consumables segment is currently dominating due to the recurring need for reagents, kits, and other consumables required for conducting assays. Conversely, the Software and Services segment is the fastest-growing, driven by the increasing demand for advanced data analysis and interpretation tools, as well as the rising adoption of integrated solutions that enhance laboratory efficiency.

Immuno Oncology Assays Market, By Application

• Research Applications
• Clinical Diagnostics

Based on Application, the Global Immuno Oncology Assays Market is segmented into Research Applications and Clinical Diagnostics. The Research Applications segment is currently dominating, driven by significant investments in cancer research and development initiatives aimed at discovering new biomarkers and therapies. However, the Clinical Diagnostics segment is the fastest-growing, fueled by the increasing adoption of immunotherapy in clinical settings and the demand for personalized treatment strategies.

Immuno Oncology Assays Market, By Indication

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Bladder Cancer
• Melanoma

Based on Indication, the Global Immuno Oncology Assays Market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer and Melanoma. The Lung Cancer segment currently dominates due to the high prevalence of the disease and the significant advancements in immunotherapy options for lung cancer patients. Conversely, the Melanoma segment is the fastest-growing, fueled by the increasing incidence of melanoma and the rapid development of innovative immunotherapies, such as immune checkpoint inhibitors, which have shown promising results in clinical trials.

Immuno Oncology Assays Market, By Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Immunoassay
• Next-Generation Sequencing (NGS)
• In Situ Hybridization (ISH)

Based on Application, the Global Immuno Oncology Assays Market is segmented into Polymerase Chain Reaction (PCR), Flow Cytometry, Immunoassay, Next-Generation Sequencing (NGS), and In Situ Hybridization (ISH). The Polymerase Chain Reaction (PCR) segment currently dominates due to its widespread use in detecting and amplifying specific DNA sequences, making it essential for various diagnostic applications in oncology. Conversely, the Next-Generation Sequencing (NGS) segment is the fastest-growing, driven by advancements in sequencing technologies and their capacity to analyze multiple genes simultaneously.

Immuno Oncology Assays Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Immuno Oncology Assays Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure.

Key Players

• The "Global Immuno Oncology Assays Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Agilent Technologies, Inc., PerkinElmer, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Crown Bioscience Inc., Merck & Company, Inc., InSphero Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Immuno Oncology Assays Market: Recent Developments
• In August 2024 Roche received U.S. Food and Drug Administration (FDA) approval for its new companion diagnostic assay that supports the use of a targeted therapy for breast cancer patients. This assay is designed to identify patients who are most likely to benefit from specific immuno-oncology treatments, thereby streamlining the patient selection process and improving treatment efficacy.
• In July 2024 Thermo Fisher Scientific announced an expansion of its immuno-oncology portfolio with the introduction of new assays for tumor microenvironment analysis. These assays are designed to provide comprehensive insights into tumor behavior and immune response, supporting researchers in their quest to develop more effective immunotherapies. The company aims to enhance its leadership in precision medicine with these innovative solutions.
• In June 2024 Agilent Technologies announced a partnership with leading academic institutions to develop novel immuno-oncology assays. This collaboration aims to accelerate research in tumor immunology and biomarker discovery, fostering innovation in the field. Agilent's CEO highlighted the importance of collaborative efforts in advancing immuno-oncology research and improving patient care through novel diagnostic solutions.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Consumables
• 5.3 Software and Services
• 5.4 Instruments

6 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Research Applications
• 6.3 Clinical Diagnostics

7 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY INDICATION

• 7.1 Overview
• 7.2 Lung Cancer
• 7.3 Breast Cancer
• 7.4 Colorectal Cancer
• 7.5 Bladder Cancer
• 7.6 Melanoma
• 7.7 Other Cancers

8 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY

• 8.1 Overview
• 8.2 Polymerase Chain Reaction (PCR)
• 8.3 Flow Cytometry
• 8.4 Immunoassay
• 8.5 Next-Generation Sequencing (NGS)
• 8.6 In Situ Hybridization (ISH)

9 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Agilent Technologies, Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Thermo Fisher Scientific, Inc.
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 PerkinElmer, Inc.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Illumina, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 PerkinElmer, Inc.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Crown Bioscience Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Development
• 11.7 InSphero, Inc.
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Merck & Company, Inc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 F.Hoffmann-La Roche Ltd.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Development
• 11.10 HTG Molecular Diagnostics, Inc.
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Development

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research